Whole-body MR in Staging Bone and Soft Tissue Metastases in Breast Cancer Patients(MetaMaRBo) — METAMARBO  

Breast Cancer Clinical Trial

Official title: Whole-body Magnetische Resonantie Voor Het Opsporen Van Bot- en Weke Delenmetastasen Bij patiënten Met Een Borstcarcinoom (MetaMaRBo)

Status Recruiting

Clinical Trial Summary

Prospective MR-imaging study : role of magnetic resonance (MR) and Diffusion weighted imaging (DWI) MR in staging and therapy assessment in breast cancer patients with bone metastases.

Clinical Trial Description

About 50 patients with a proven breast cancer and bone metastases will be included.

First step : staging

• nuclear bone scan

• Positron Emission Tomography (PET/CT)

• MR (whole body short tau inversion recovery (STIR)-sequence and T1-sequence and Diffusion weighted imaging (DWI),no contrast administration

Aim :

• Validation of whole body diffusion weighted imaging in detection of bone metastases and visceral metastases, comparing to Bone scan en PET/CT results.

• To calculate cut-off values for DWI for bone and visceral metastases.

Second step : therapy follow-up/therapy assessment.

• Two groups of patients (oncologist takes the decision about therapy)

1. Patients treated by chemotherapy

2. Patients treated by hormonal therapy

• on week 3, 12-16 and 52 in the chemotherapy or hormonal therapy-setting, a whole body MR (same protocol, no contrast) will be performed.

End-point:

Whole body MR with DWI is useful and reliable to assess the treatment response. ;

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

• NCT number: NCT01291082
• Study type: Observational
• Source: Universitaire Ziekenhuizen Leuven
• Contact: Steven Pans
• Phone: 003216340505
• Email: steven.pans@uzleuven.be
• Status: Recruiting
• Phase: N/A
• Start date: February 2011
• Completion date: August 2013